Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FBP1 | P09467 | 1/20 | 0.54 |
| ▸ | VCP | P55072 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640452 | 1.00 | MAPT (0.60) | MAPTRAB9AALDH1A1NPC1NFE2L2 | |
| SCHEMBL30633018 | 1.00 | MAPT (0.60) | MAPTRAB9AALDH1A1NPC1NFE2L2 | |
| SCHEMBL30632956 | 0.82 | RAB9A (0.58) | MAPTRAB9ANPC1CYP19A1MEN1 | |
| SCHEMBL15498134 | 0.80 | NFE2L2 (0.89) | MAPTRAB9AALDH1A1NPC1NFE2L2 | |
| SCHEMBL11301074 | 0.77 | CYP19A1 (0.93) | MAPTRAB9AALDH1A1NPC1NFE2L2 | |
| SCHEMBL11301072 | 0.77 | CYP19A1 (0.93) | MAPTRAB9AALDH1A1NPC1NFE2L2 | |
| SCHEMBL5894264 | 0.76 | NFE2L2 (0.75) | MAPTRAB9AALDH1A1NPC1NFE2L2 | |
| SCHEMBL5894256 | 0.76 | NFE2L2 (0.75) | MAPTRAB9AALDH1A1NPC1NFE2L2 | |
| SCHEMBL30632879 | 0.76 | ALDH1A1 (0.39) | MAPTRAB9AALDH1A1NPC1MEN1 | |
| SCHEMBL4710212 | 0.75 | RAB9A (1.00) | MAPTRAB9AALDH1A1NPC1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350165-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20220081390-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| CN-108349893-B | Farnesoid X receptor agonists and uses thereof | 梅塔克林公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20180282263-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2018-10-04 | — | — | US | disclosed |
| EP-3350165-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017049173-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049173-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885RAB9A 2088/4885ALDH1A1 2205/4885 |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885RAB9A 2088/4885ALDH1A1 2205/4885 |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885RAB9A 2088/4885ALDH1A1 2205/4885 |
| US-20180282263-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885RAB9A 2088/4885ALDH1A1 2205/4885 |
| US-20220081390-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885RAB9A 2088/4885ALDH1A1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.